文献速递前列腺癌

橙剂暴露对前列腺癌结局的影响

The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.
PubMed 文献 · J Urol · 2019-01-01

本研究基于美国退伍军人事务部全国数据库,回顾性分析2000至2008年诊断并接受雄激素剥夺治疗晚期前列腺癌的87344例患者,比较橙剂暴露组3475例与非暴露组83869例的结局。经逆概率加权调整后,橙剂暴露与总生存改善相关(HR 0.84,95%CI 0.73-0.97,p=0.02),骨骼相关事件风险和癌症特异性生存无显著差异。

要点

  • 橙剂暴露与接受ADT的晚期前列腺癌患者总生存改善相关(HR 0.84,95%CI 0.73-0.97)。
  • 橙剂暴露与骨骼相关事件风险无显著关联(HR 1.04,95%CI 0.80-1.35,p=0.77)。
  • 橙剂暴露与癌症特异性生存无显著差异(HR 0.79,95%CI 0.60-1.03,p=0.08)。

核心结论

  • 橙剂暴露与接受雄激素剥夺治疗的晚期前列腺癌患者死亡风险降低相关,未显示与更差肿瘤学结局相关。

研究设计与样本

  • 回顾性队列研究,基于美国退伍军人事务部全国数据库,纳入2000至2008年诊断的前列腺癌患者,随访至2016年5月。
  • 共识别87344例患者,其中橙剂暴露组3475例,非暴露组83869例。
  • 采用逆概率加权(IPSW)调整后的Cox比例风险模型分析橙剂暴露与总生存、骨骼相关事件及癌症特异性生存的关联。

主要发现

  • 橙剂暴露组患者更年轻(p<0.001)、前列腺特异性抗原更低(p=0.002),且更可能接受局部治疗和化疗(p<0.001)。
  • 两组Charlson合并症指数相似(p=0.40)。
  • 经IPSW调整后,橙剂暴露与总生存改善相关(HR 0.84,95%CI 0.73-0.97,p=0.02)。
  • 橙剂暴露与骨骼相关事件风险无显著差异(HR 1.04,95%CI 0.80-1.35,p=0.77)。
  • 橙剂暴露与癌症特异性生存无显著差异(HR 0.79,95%CI 0.60-1.03,p=0.08)。

临床怎么用

  • 对于有橙剂暴露史的晚期前列腺癌患者,接受雄激素剥夺治疗时无需因暴露史而担忧更差肿瘤学结局。
  • 橙剂暴露史可能与总生存改善相关,但需结合个体情况综合评估,不应作为治疗决策的唯一依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study we explored the effect of Agent Orange exposure on prostate cancer survival in VA (Veterans Affairs) patients receiving androgen deprivation therapy for advanced prostate cancer. MATERIALS AND METHODS: We retrospectively examined the association between Agent Orange exposure in men with prostate cancer in national VA databases who were being treated with androgen deprivation therapy. Patients were diagnosed with prostate cancer from 2000 to 2008 with followup through May 2016. Clinical, pathological and demographic variables were compared by Agent Orange exposure. Associations of Agent Orange with overall survival, skeletal related events and cancer specific survival were performed using adjusted Cox proportional hazard models after IPSW (inverse propensity score weighted) adjustment. RESULTS: Overall 87,344 patients were identified. The 3,475 Agent Orange exposed patients were younger (p <0.001), had lower prostate specific antigen (p = 0.002) and were more likely to receive local therapy and chemotherapy (p <0.001) than the 83,869 nonexposed patients. The Charlson comorbidity index was similar in the groups (p = 0.40). After IPSW adjustment Agent Orange exposure was associated with improved overall survival (HR 0.84, 95% CI 0.73-0.97, p = 0.02). However, no difference was observed in the risk of skeletal related events (HR 1.04, 95% CI 0.80-1.35, p = 0.77) or cancer specific survival (HR 0.79, 95% CI 0.60-1.03, p = 0.08). CONCLUSIONS: Agent Orange exposure was associated with a decreased risk of death in men receiving androgen deprivation therapy for advanced prostate cancer. It does not appear to be associated with worse oncologic outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Etheridge T, Liou JI, Downs TM, et al. The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. J Urol. 2019. PMID: 30321553. doi:10.1016/j.juro.2018.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。